Menu
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 7
MicroRNA binding site polymorphisms as biomarkers in cancer management and research
Authors Cipollini M, Landi S, Gemignani F
Received 31 January 2014
Accepted for publication 2 May 2014
Published 23 July 2014 Volume 2014:7 Pages 173—191
DOI https://doi.org/10.2147/PGPM.S61693
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 5
Monica Cipollini, Stefano Landi*, Federica Gemignani*
Department of Biology, University of Pisa, Pisa, Italy
*These authors contributed equally to this work
Abstract: MicroRNAs (miRNAs) are important regulators of eukaryotic gene expression. They have been implicated in a broad range of biological processes, and miRNA-related genetic alterations probably underlie several human diseases. Single nucleotide polymorphisms of transcripts may modulate the posttranscriptional regulation of gene expression by miRNAs and explain interindividual variability in cancer risk and in chemotherapy response. On the basis of recent association studies published in the literature, the present review mainly summarizes the potential role of miRNAs as molecular biomarkers for disease susceptibility, diagnosis, prognosis, and drug-response prediction in tumors. Many clues suggest a role for polymorphisms within the 3' untranslated regions of KRAS rs61764370, SET8 rs16917496, and MDM4 rs4245739 as SNPs in miRNA binding sites highly promising in the biology of human cancer. However, more studies are needed to better characterize the composite spectrum of genetic determinants for future use of markers in risk prediction and clinical management of diseases, heading toward personalized medicine.
Keywords: miRSNP, 3'-UTR target binding site, cancer risk, biomarkers
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.